Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 16/20 | 0.54 |
| ▸ | F2 | P00734 | 4/20 | 0.54 |
| ▸ | KLK1 | P06870 | 4/20 | 0.54 |
| ▸ | TMPRSS15 | P98073 | 11/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ACR | P10323 | 1/20 | 0.41 |
| ▸ | PPID | Q08752 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3239689 | 1.00 | PRSS1 (0.54) | PRSS1F2KLK1TMPRSS15KDM4E | |
| SCHEMBL3245001 | 0.90 | PRSS1 (0.57) | PRSS1F2KLK1TMPRSS15KDM4E | |
| SCHEMBL7303523 | 0.90 | PRSS1 (0.57) | PRSS1F2KLK1TMPRSS15KDM4E | |
| SCHEMBL3236057 | 0.89 | PRSS1 (0.53) | PRSS1F2KLK1TMPRSS15KDM4E | |
| SCHEMBL3241531 | 0.88 | PRSS1 (0.58) | PRSS1F2KLK1TMPRSS15KDM4E | |
| SCHEMBL7302516 | 0.88 | PRSS1 (0.58) | PRSS1F2KLK1TMPRSS15KDM4E | |
| SCHEMBL3238646 | 0.87 | PRSS1 (0.53) | PRSS1F2KLK1TMPRSS15KDM4E | |
| SCHEMBL3238801 | 0.87 | PRSS1 (0.53) | PRSS1F2KLK1TMPRSS15KDM4E | |
| SCHEMBL3238579 | 0.87 | PRSS1 (0.56) | PRSS1F2KLK1TMPRSS15KDM4E | |
| SCHEMBL3243407 | 0.86 | PRSS1 (0.54) | PRSS1F2KLK1TMPRSS15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671057-B2 | Therapeutic agent for type II diabetes comprising protease-inhibiting compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20080009537-A1 | Therapeutic Agent for Diabetes Comprising Protease-Inhibiting Compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009537-A1 | Therapeutic Agent for Diabetes Comprising Protease-Inhibiting Compound | DPP4, IAPP, DPP7 | PRSS1 25/4885F2 805/4885KLK1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.